Company news

Xilio Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Xilio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 26, 2023

Xilio Therapeutics Announces Promotion of Katarina Luptakova, M.D., to Chief Medical Officer and Scott Coleman, Ph.D., to Chief Development Officer

September 4, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2023 Financial Results

August 13, 2023

Xilio Therapeutics Announces Promotion of Chris Frankenfield to Chief Operating Officer

August 2, 2023

Xilio Therapeutics Announces Preliminary Clinical Data from Phase 1 Trial of XTX101, a Tumor-Activated, Fc-Enhanced Anti-CTLA-4, in Patients with Advanced Solid Tumors

May 24, 2023

Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2023 Financial Results

May 8, 2023

Xilio Therapeutics Announces Pipeline and Business Updates for the Fourth Quarter and Full Year 2022 Financial Results

March 1, 2023

Xilio Therapeutics to Host Live Virtual Program Spotlighting XTX301, a Tumor-Activated IL-12

November 22, 2022

Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2022 Financial Results

November 8, 2022

Xilio Therapeutics Appoints Tomas J. Heyman to Board of Directors

September 14, 2022

Xilio Therapeutics Announces Encouraging Preliminary Phase 1 Dose-Escalation Data for XTX101, a Tumor-Selective Anti-CTLA-4, and Reports Pipeline and Business Updates and Second Quarter 2022 Financial Results

August 8, 2022

Xilio Therapeutics Announces Promotion of Martin Huber, M.D., to President

June 15, 2022

Xilio Therapeutics Appoints Stacey Davis as Chief Business Officer

May 16, 2022

Xilio Therapeutics Reports Pipeline and Business Highlights and First Quarter 2022 Financial Results

May 11, 2022

Xilio Therapeutics Announces Initiation of Patient Dosing in Phase 1/2 Clinical Trial of XTX202 for the Treatment of Patients with Solid Tumors

January 19, 2022

Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors

January 5, 2022

Xilio Therapeutics Reports Pipeline and Business Progress and Third Quarter 2021 Financial Results

December 1, 2021

Xilio Therapeutics Announces Preclinical Data Demonstrating Anti-Tumor Activity and Tolerability of XTX301, a Tumor-Selective IL-12, at Society for Immunotherapy in Cancer Annual Meeting

November 11, 2021

Xilio Therapeutics Announces Closing of Initial Public Offering

October 25, 2021

← Newer news releases

Decks

The 5 newest of 11 decks. Every deck is listed under its year.